person · Reporting owner

Hassan Fred

Disclosed activity across 8 companies

Tapewire entity: 11868
SEC CIK: 0001110744

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
AMGEN INCAMGN · Entity 2832	Director	May 05, 2020	May 08, 2020
BridgeBio Pharma, Inc.BBIO · Entity 3360	Director	June 22, 2026	June 24, 2026
Cocrystal Pharma, Inc.COCP · Entity 7621	Director	January 09, 2026	January 13, 2026
EyePoint, Inc.EYPT · Entity 5702	Director	January 02, 2026	January 06, 2026
PRECIGEN, INC.PGEN · Entity 4356	Director	March 13, 2026	March 16, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

AMGEN INC

Report date May 05, 2020 · Filed May 08, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	9,191	Reported balance After 2020-05-05 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2020-05-05 · Grant · Acquired 846 · Balance 9,191 F1: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule.

Filing footnotes · ownership attribution and instrument terms

F1: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule.

BridgeBio Pharma, Inc.

Report date June 22, 2026 · Filed June 24, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	29,879	Reported balance After 2026-06-22 transaction · row 1 1 source row Row 1 · 2026-06-22 · Grant · Acquired 3,990 · Balance 29,879 F1: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date. F2: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $68.92 · Expires 2036-06-21	Direct	5,277	Reported balance After 2026-06-22 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-22 · Grant · Acquired 5,277 · Balance 5,277 F3: The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.

F2: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F3: The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.

Cocrystal Pharma, Inc.

Report date January 09, 2026 · Filed January 13, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.10 · Expires 2036-01-09	Direct	16,410	Reported balance After 2026-01-09 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-01-09 · Grant · Acquired 16,410 · Balance 16,410 F1: The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Compensation Committee of the Board of Directors. The non-qualified stock options are granted under the Issuer's 2025 Equity Incentive Plan and the exercisability shall be subject to execution of the Issuer's form of Non-Qualified Stock Option Agreement. The non-qualified stock options shall vest as follows: one-half shall vest and become exercisable on January 9, 2027 and the remaining half shall vest and become exercisable in eight equal quarterly installments commencing on March 31, 2027, subject to the Reporting Person continuing to serve as a director of the Issuer on each applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Compensation Committee of the Board of Directors. The non-qualified stock options are granted under the Issuer's 2025 Equity Incentive Plan and the exercisability shall be subject to execution of the Issuer's form of Non-Qualified Stock Option Agreement. The non-qualified stock options shall vest as follows: one-half shall vest and become exercisable on January 9, 2027 and the remaining half shall vest and become exercisable in eight equal quarterly installments commencing on March 31, 2027, subject to the Reporting Person continuing to serve as a director of the Issuer on each applicable vesting date.

EyePoint, Inc.

Report date January 02, 2026 · Filed January 06, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.48 · Expires 2036-01-02	Direct	40,000	Reported balance After 2026-01-02 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-01-02 · Grant · Acquired 40,000 · Balance 40,000

PRECIGEN, INC.

Report date March 13, 2026 · Filed March 16, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,243,239	Reported balance After 2026-03-13 transaction · row 1 1 source row Row 1 · 2026-03-13 · Exercise / conversion · Acquired 71,839 · Balance 1,243,239 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-03-13 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-03-13 · Exercise / conversion · Disposed 71,839 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. F2: The RSUs vested in full on March 13, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock.

F2: The RSUs vested in full on March 13, 2026.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Merck & Co., Inc.

Report date November 03, 2009 · Filed November 04, 2009

Section 16 reporting ended · disclosed 2009-11-04. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common SharesSEC Table I · non-derivative	Direct	Reported balance After 2009-11-03 transaction · row 1 1 source row Row 1 · 2009-11-03 · Disposition to issuer · Disposed 935,400 · Balance 0 F1: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Merck & Co., Inc. ("Merger"), upon closing of the Merger, each common share of the Issuer was converted into 0.5767 shares of Merck & Co., Inc. common stock and $10.50 in cash.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.43 · Expires 2013-04-19	Direct	Reported balance After 2009-11-03 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2009-11-03 · Disposition to issuer · Disposed 900,000 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.23 · Expires 2013-05-18	Direct	Reported balance After 2009-11-03 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2009-11-03 · Disposition to issuer · Disposed 1,000,000 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.57 · Expires 2014-04-30	Direct	Reported balance After 2009-11-03 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2009-11-03 · Disposition to issuer · Disposed 1,180,000 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.70 · Expires 2015-04-24	Direct	Reported balance After 2009-11-03 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2009-11-03 · Disposition to issuer · Disposed 1,100,000 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.85 · Expires 2015-04-30	Direct	Reported balance After 2009-11-03 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2009-11-03 · Disposition to issuer · Disposed 836,000 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.91 · Expires 2016-04-30	Direct	Reported balance After 2009-11-03 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2009-11-03 · Disposition to issuer · Disposed 868,300 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter.
Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.20 · Expires 2014-02-22	Direct	Reported balance After 2009-11-03 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2009-11-03 · Disposition to issuer · Disposed 1,100,000 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter.
Phantom Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2009-11-03 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2009-11-03 · Disposition to issuer · Disposed 196,761.57 · Balance 0 F4: Each unit of phantom stock is the economic equivalent of one share of common stock. F5: In connection with the Merger, each unit of phantom stock was converted into 0.5767 phantom shares of Merck & Co., Inc. common stock and $10.50 in cash. The cash value of the phantom stock units will be paid to the reporting person in accordance with the reporting person's distribution election under the Issuer's nonqualified deferred compensation plan.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Merck & Co., Inc. ("Merger"), upon closing of the Merger, each common share of the Issuer was converted into 0.5767 shares of Merck & Co., Inc. common stock and $10.50 in cash.

F2: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter.

F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement.

F4: Each unit of phantom stock is the economic equivalent of one share of common stock.

F5: In connection with the Merger, each unit of phantom stock was converted into 0.5767 phantom shares of Merck & Co., Inc. common stock and $10.50 in cash. The cash value of the phantom stock units will be paid to the reporting person in accordance with the reporting person's distribution election under the Issuer's nonqualified deferred compensation plan.

Prometheus Biosciences, Inc.

Report date June 16, 2023 · Filed June 16, 2023

Section 16 reporting ended · disclosed 2023-06-16. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2023-06-16 transaction · row 1 1 source row Row 1 · 2023-06-16 · Disposition to issuer · Disposed 2,123 · Balance 0 F1: Reflects restricted stock units. F2: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,.. (Continued in Footnote 3) F3: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.82 · Expires 2031-05-13	Direct	Reported balance After 2023-06-16 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-06-16 · Disposition to issuer · Disposed 40,000 · Balance 0 F2: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,.. (Continued in Footnote 3) F3: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.32 · Expires 2031-11-13	Direct	Reported balance After 2023-06-16 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-06-16 · Disposition to issuer · Disposed 541 · Balance 0 F2: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,.. (Continued in Footnote 3) F3: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.02 · Expires 2032-05-18	Direct	Reported balance After 2023-06-16 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-06-16 · Disposition to issuer · Disposed 21,013 · Balance 0 F2: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,.. (Continued in Footnote 3) F3: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects restricted stock units.

F2: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,.. (Continued in Footnote 3)

F3: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option.

WARNER MEDIA, LLC

Report date June 14, 2018 · Filed June 18, 2018

Section 16 reporting ended · disclosed 2018-06-18. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common Stock, Par Value $.01SEC Table I · non-derivative	Direct	Reported balance After 2018-06-14 transaction · row 1 1 source row Row 1 · 2018-06-14 · Disposition to issuer · Disposed 49,089 · Balance 0 F1: On June 14, 2018, AT&T Inc., a Delaware corporation ("AT&T"), acquired Time Warner Inc. (the "Company") pursuant to that certain Agreement and Plan of Merger, dated October 22, 2016, by and among the Company, AT&T, West Merger Sub, Inc., a wholly owned subsidiary of AT&T, and West Merger Sub II, LLC, a wholly owned subsidiary of AT&T (the "Merger Agreement"). The acquisition is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on January 9, 2017. In accordance with the terms of the Merger Agreement, each share of the Company's common stock was exchanged for 1.437 shares of AT&T common stock plus $53.75 in cash. Each disposition reported in this Form 4 is an exempt disposition.
Director Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.39 · Expires 2019-10-28	Direct	Reported balance After 2018-06-14 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2018-06-14 · Disposition to issuer · Disposed 4,019 · Balance 0 F1: On June 14, 2018, AT&T Inc., a Delaware corporation ("AT&T"), acquired Time Warner Inc. (the "Company") pursuant to that certain Agreement and Plan of Merger, dated October 22, 2016, by and among the Company, AT&T, West Merger Sub, Inc., a wholly owned subsidiary of AT&T, and West Merger Sub II, LLC, a wholly owned subsidiary of AT&T (the "Merger Agreement"). The acquisition is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on January 9, 2017. In accordance with the terms of the Merger Agreement, each share of the Company's common stock was exchanged for 1.437 shares of AT&T common stock plus $53.75 in cash. Each disposition reported in this Form 4 is an exempt disposition. F2: Pursuant to the Merger Agreement, each outstanding option to purchase the Company's common stock (a "Company Option"), whether vested or unvested, was converted into an option to acquire a number of shares of AT&T common stock equal to the number of shares of Company common stock under such Company Option, subject to the vesting and other terms in the applicable Company Option award agreement, except that the exercise price and the number of shares of AT&T common stock issuable upon exercise of such Company Option were adjusted based on the option exchange ratio determined under a formula in the Merger Agreement (which yields approximately 3.0757).
Director Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.84 · Expires 2020-05-21	Direct	Reported balance After 2018-06-14 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2018-06-14 · Disposition to issuer · Disposed 5,708 · Balance 0 F1: On June 14, 2018, AT&T Inc., a Delaware corporation ("AT&T"), acquired Time Warner Inc. (the "Company") pursuant to that certain Agreement and Plan of Merger, dated October 22, 2016, by and among the Company, AT&T, West Merger Sub, Inc., a wholly owned subsidiary of AT&T, and West Merger Sub II, LLC, a wholly owned subsidiary of AT&T (the "Merger Agreement"). The acquisition is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on January 9, 2017. In accordance with the terms of the Merger Agreement, each share of the Company's common stock was exchanged for 1.437 shares of AT&T common stock plus $53.75 in cash. Each disposition reported in this Form 4 is an exempt disposition. F2: Pursuant to the Merger Agreement, each outstanding option to purchase the Company's common stock (a "Company Option"), whether vested or unvested, was converted into an option to acquire a number of shares of AT&T common stock equal to the number of shares of Company common stock under such Company Option, subject to the vesting and other terms in the applicable Company Option award agreement, except that the exercise price and the number of shares of AT&T common stock issuable upon exercise of such Company Option were adjusted based on the option exchange ratio determined under a formula in the Merger Agreement (which yields approximately 3.0757).
Director Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.81 · Expires 2022-05-15	Direct	Reported balance After 2018-06-14 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2018-06-14 · Disposition to issuer · Disposed 5,336 · Balance 0 F1: On June 14, 2018, AT&T Inc., a Delaware corporation ("AT&T"), acquired Time Warner Inc. (the "Company") pursuant to that certain Agreement and Plan of Merger, dated October 22, 2016, by and among the Company, AT&T, West Merger Sub, Inc., a wholly owned subsidiary of AT&T, and West Merger Sub II, LLC, a wholly owned subsidiary of AT&T (the "Merger Agreement"). The acquisition is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on January 9, 2017. In accordance with the terms of the Merger Agreement, each share of the Company's common stock was exchanged for 1.437 shares of AT&T common stock plus $53.75 in cash. Each disposition reported in this Form 4 is an exempt disposition. F2: Pursuant to the Merger Agreement, each outstanding option to purchase the Company's common stock (a "Company Option"), whether vested or unvested, was converted into an option to acquire a number of shares of AT&T common stock equal to the number of shares of Company common stock under such Company Option, subject to the vesting and other terms in the applicable Company Option award agreement, except that the exercise price and the number of shares of AT&T common stock issuable upon exercise of such Company Option were adjusted based on the option exchange ratio determined under a formula in the Merger Agreement (which yields approximately 3.0757).
Director Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.27 · Expires 2021-05-20	Direct	Reported balance After 2018-06-14 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2018-06-14 · Disposition to issuer · Disposed 4,880 · Balance 0 F1: On June 14, 2018, AT&T Inc., a Delaware corporation ("AT&T"), acquired Time Warner Inc. (the "Company") pursuant to that certain Agreement and Plan of Merger, dated October 22, 2016, by and among the Company, AT&T, West Merger Sub, Inc., a wholly owned subsidiary of AT&T, and West Merger Sub II, LLC, a wholly owned subsidiary of AT&T (the "Merger Agreement"). The acquisition is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on January 9, 2017. In accordance with the terms of the Merger Agreement, each share of the Company's common stock was exchanged for 1.437 shares of AT&T common stock plus $53.75 in cash. Each disposition reported in this Form 4 is an exempt disposition. F2: Pursuant to the Merger Agreement, each outstanding option to purchase the Company's common stock (a "Company Option"), whether vested or unvested, was converted into an option to acquire a number of shares of AT&T common stock equal to the number of shares of Company common stock under such Company Option, subject to the vesting and other terms in the applicable Company Option award agreement, except that the exercise price and the number of shares of AT&T common stock issuable upon exercise of such Company Option were adjusted based on the option exchange ratio determined under a formula in the Merger Agreement (which yields approximately 3.0757).
Director Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $67.84 · Expires 2024-06-13	Direct	Reported balance After 2018-06-14 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2018-06-14 · Disposition to issuer · Disposed 2,898 · Balance 0 F1: On June 14, 2018, AT&T Inc., a Delaware corporation ("AT&T"), acquired Time Warner Inc. (the "Company") pursuant to that certain Agreement and Plan of Merger, dated October 22, 2016, by and among the Company, AT&T, West Merger Sub, Inc., a wholly owned subsidiary of AT&T, and West Merger Sub II, LLC, a wholly owned subsidiary of AT&T (the "Merger Agreement"). The acquisition is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on January 9, 2017. In accordance with the terms of the Merger Agreement, each share of the Company's common stock was exchanged for 1.437 shares of AT&T common stock plus $53.75 in cash. Each disposition reported in this Form 4 is an exempt disposition. F2: Pursuant to the Merger Agreement, each outstanding option to purchase the Company's common stock (a "Company Option"), whether vested or unvested, was converted into an option to acquire a number of shares of AT&T common stock equal to the number of shares of Company common stock under such Company Option, subject to the vesting and other terms in the applicable Company Option award agreement, except that the exercise price and the number of shares of AT&T common stock issuable upon exercise of such Company Option were adjusted based on the option exchange ratio determined under a formula in the Merger Agreement (which yields approximately 3.0757).
Director Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.83 · Expires 2023-05-23	Direct	Reported balance After 2018-06-14 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2018-06-14 · Disposition to issuer · Disposed 2,996 · Balance 0 F1: On June 14, 2018, AT&T Inc., a Delaware corporation ("AT&T"), acquired Time Warner Inc. (the "Company") pursuant to that certain Agreement and Plan of Merger, dated October 22, 2016, by and among the Company, AT&T, West Merger Sub, Inc., a wholly owned subsidiary of AT&T, and West Merger Sub II, LLC, a wholly owned subsidiary of AT&T (the "Merger Agreement"). The acquisition is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on January 9, 2017. In accordance with the terms of the Merger Agreement, each share of the Company's common stock was exchanged for 1.437 shares of AT&T common stock plus $53.75 in cash. Each disposition reported in this Form 4 is an exempt disposition. F2: Pursuant to the Merger Agreement, each outstanding option to purchase the Company's common stock (a "Company Option"), whether vested or unvested, was converted into an option to acquire a number of shares of AT&T common stock equal to the number of shares of Company common stock under such Company Option, subject to the vesting and other terms in the applicable Company Option award agreement, except that the exercise price and the number of shares of AT&T common stock issuable upon exercise of such Company Option were adjusted based on the option exchange ratio determined under a formula in the Merger Agreement (which yields approximately 3.0757).
Director Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $72.37 · Expires 2026-06-17	Direct	Reported balance After 2018-06-14 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2018-06-14 · Disposition to issuer · Disposed 3,108 · Balance 0 F1: On June 14, 2018, AT&T Inc., a Delaware corporation ("AT&T"), acquired Time Warner Inc. (the "Company") pursuant to that certain Agreement and Plan of Merger, dated October 22, 2016, by and among the Company, AT&T, West Merger Sub, Inc., a wholly owned subsidiary of AT&T, and West Merger Sub II, LLC, a wholly owned subsidiary of AT&T (the "Merger Agreement"). The acquisition is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on January 9, 2017. In accordance with the terms of the Merger Agreement, each share of the Company's common stock was exchanged for 1.437 shares of AT&T common stock plus $53.75 in cash. Each disposition reported in this Form 4 is an exempt disposition. F2: Pursuant to the Merger Agreement, each outstanding option to purchase the Company's common stock (a "Company Option"), whether vested or unvested, was converted into an option to acquire a number of shares of AT&T common stock equal to the number of shares of Company common stock under such Company Option, subject to the vesting and other terms in the applicable Company Option award agreement, except that the exercise price and the number of shares of AT&T common stock issuable upon exercise of such Company Option were adjusted based on the option exchange ratio determined under a formula in the Merger Agreement (which yields approximately 3.0757).
Director Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $88.00 · Expires 2025-06-19	Direct	Reported balance After 2018-06-14 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2018-06-14 · Disposition to issuer · Disposed 2,460 · Balance 0 F1: On June 14, 2018, AT&T Inc., a Delaware corporation ("AT&T"), acquired Time Warner Inc. (the "Company") pursuant to that certain Agreement and Plan of Merger, dated October 22, 2016, by and among the Company, AT&T, West Merger Sub, Inc., a wholly owned subsidiary of AT&T, and West Merger Sub II, LLC, a wholly owned subsidiary of AT&T (the "Merger Agreement"). The acquisition is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on January 9, 2017. In accordance with the terms of the Merger Agreement, each share of the Company's common stock was exchanged for 1.437 shares of AT&T common stock plus $53.75 in cash. Each disposition reported in this Form 4 is an exempt disposition. F2: Pursuant to the Merger Agreement, each outstanding option to purchase the Company's common stock (a "Company Option"), whether vested or unvested, was converted into an option to acquire a number of shares of AT&T common stock equal to the number of shares of Company common stock under such Company Option, subject to the vesting and other terms in the applicable Company Option award agreement, except that the exercise price and the number of shares of AT&T common stock issuable upon exercise of such Company Option were adjusted based on the option exchange ratio determined under a formula in the Merger Agreement (which yields approximately 3.0757).
Phantom Stock UnitsSEC Table II · derivative / convertible security · Expires 2018-06-14	IndirectBy Deferred Compensation Plan	Reported balance After 2018-06-14 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2018-06-14 · Disposition to issuer · Disposed 1,128.3387 · Balance 0 F3: Pursuant to the Merger Agreement, each outstanding phantom stock unit with respect to the Company's common stock acquired pursuant to the Time Warner Inc. Non-Employee Directors' Deferred Compensation Plan (the "Deferred Compensation Plan") was deemed converted into an amount in cash equal to approximately $100.8845 and reinvested in the investment option under the Deferred Compensation Plan that earns interest at a specified rate. Pursuant to the terms of the Deferred Compensation Plan, the amount credited to the account will be paid out in cash in a lump sum or in annual installments beginning on April 30, 2019. F1: On June 14, 2018, AT&T Inc., a Delaware corporation ("AT&T"), acquired Time Warner Inc. (the "Company") pursuant to that certain Agreement and Plan of Merger, dated October 22, 2016, by and among the Company, AT&T, West Merger Sub, Inc., a wholly owned subsidiary of AT&T, and West Merger Sub II, LLC, a wholly owned subsidiary of AT&T (the "Merger Agreement"). The acquisition is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on January 9, 2017. In accordance with the terms of the Merger Agreement, each share of the Company's common stock was exchanged for 1.437 shares of AT&T common stock plus $53.75 in cash. Each disposition reported in this Form 4 is an exempt disposition.

Filing footnotes · ownership attribution and instrument terms

F1: On June 14, 2018, AT&T Inc., a Delaware corporation ("AT&T"), acquired Time Warner Inc. (the "Company") pursuant to that certain Agreement and Plan of Merger, dated October 22, 2016, by and among the Company, AT&T, West Merger Sub, Inc., a wholly owned subsidiary of AT&T, and West Merger Sub II, LLC, a wholly owned subsidiary of AT&T (the "Merger Agreement"). The acquisition is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on January 9, 2017. In accordance with the terms of the Merger Agreement, each share of the Company's common stock was exchanged for 1.437 shares of AT&T common stock plus $53.75 in cash. Each disposition reported in this Form 4 is an exempt disposition.

F2: Pursuant to the Merger Agreement, each outstanding option to purchase the Company's common stock (a "Company Option"), whether vested or unvested, was converted into an option to acquire a number of shares of AT&T common stock equal to the number of shares of Company common stock under such Company Option, subject to the vesting and other terms in the applicable Company Option award agreement, except that the exercise price and the number of shares of AT&T common stock issuable upon exercise of such Company Option were adjusted based on the option exchange ratio determined under a formula in the Merger Agreement (which yields approximately 3.0757).

F3: Pursuant to the Merger Agreement, each outstanding phantom stock unit with respect to the Company's common stock acquired pursuant to the Time Warner Inc. Non-Employee Directors' Deferred Compensation Plan (the "Deferred Compensation Plan") was deemed converted into an amount in cash equal to approximately $100.8845 and reinvested in the investment option under the Deferred Compensation Plan that earns interest at a specified rate. Pursuant to the terms of the Deferred Compensation Plan, the amount credited to the account will be paid out in cash in a lump sum or in annual installments beginning on April 30, 2019.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 22, 2026 Filed Jun 24, 2026 22:05 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	GrantStock Option (Right to Buy) · Derivative	5,277	$0.00 Strike: $68.92	$0.00	Disclosure SEC source: 0001470831-26-000629 · wk-form4_1782338741.xml · derivative · entry 2 Hassan Fred · CIK 0001110744 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,277 Underlying: Common Stock · 5,277 shares Expires 2036-06-21 F3 · derivative.exercise_date: The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date. Read SEC document
June 22, 2026 Filed Jun 24, 2026 22:05 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	GrantCommon Stock	3,990	$0.00	$0.00	Disclosure SEC source: 0001470831-26-000629 · wk-form4_1782338741.xml · nonDerivative · entry 1 Hassan Fred · CIK 0001110744 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,879 F1 · kind: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document
March 13, 2026 Filed Mar 16, 2026 21:08 UTC	PRECIGEN, INC. PGEN · Entity 4356	Exercise / conversionRestricted Stock Units · Derivative	71,839	$0.00	$0.00	Disclosure SEC source: 0000950103-26-003833 · ownership.xml · derivative · entry 2 Hassan Fred · CIK 0001110744 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 71,839 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. F2 · derivative.exercise_date: The RSUs vested in full on March 13, 2026. F2 · derivative.expiration_date: The RSUs vested in full on March 13, 2026. Read SEC document
March 13, 2026 Filed Mar 16, 2026 21:08 UTC	PRECIGEN, INC. PGEN · Entity 4356	Exercise / conversionCommon Stock	71,839	Not disclosed	Not disclosed	Disclosure SEC source: 0000950103-26-003833 · ownership.xml · nonDerivative · entry 1 Hassan Fred · CIK 0001110744 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,243,239 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. Read SEC document
March 10, 2026 Filed Mar 12, 2026 20:26 UTC	PRECIGEN, INC. PGEN · Entity 4356	GrantOption to Purchase Common Stock (Right to Buy) · Derivative	41,073	$0.00 Strike: $3.51	$0.00	Disclosure SEC source: 0000950103-26-003687 · dp243215_4-hassan.xml · derivative · entry 3 Hassan Fred · CIK 0001110744 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,073 Underlying: Common Stock · 41,073 shares Expires 2036-03-10 Read SEC document
March 10, 2026 Filed Mar 12, 2026 20:26 UTC	PRECIGEN, INC. PGEN · Entity 4356	GrantRestricted Stock Units · Derivative	35,612	$0.00	$0.00	Disclosure SEC source: 0000950103-26-003687 · dp243215_4-hassan.xml · derivative · entry 2 Hassan Fred · CIK 0001110744 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,612 Underlying: Common Stock · 35,612 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. F3 · derivative.exercise_date: The RSUs vest in full on March 10, 2027. F3 · derivative.expiration_date: The RSUs vest in full on March 10, 2027. Read SEC document
March 10, 2026 Filed Mar 12, 2026 20:26 UTC	PRECIGEN, INC. PGEN · Entity 4356	GrantCommon Stock	17,948	$3.51	$62,997.48	Disclosure SEC source: 0000950103-26-003687 · dp243215_4-hassan.xml · nonDerivative · entry 1 Hassan Fred · CIK 0001110744 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,171,400 F1 · price: The shares were issued to the reporting person in lieu of an annual retainer of $63,000. Read SEC document
January 09, 2026 Filed Jan 13, 2026 21:10 UTC	Cocrystal Pharma, Inc. COCP · Entity 7621	GrantStock Options (Right to Buy) · Derivative	16,410	$0.00 Strike: $1.10	$0.00	Disclosure SEC source: 0001493152-26-002037 · ownership.xml · derivative · entry 1 Hassan Fred · CIK 0001110744 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,410 Underlying: Common Stock · 16,410 shares Expires 2036-01-09 F1 · security: The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Compensation Committee of the Board of Directors. The non-qualified stock options are granted under the Issuer's 2025 Equity Incentive Plan and the exercisability shall be subject to execution of the Issuer's form of Non-Qualified Stock Option Agreement. The non-qualified stock options shall vest as follows: one-half shall vest and become exercisable on January 9, 2027 and the remaining half shall vest and become exercisable in eight equal quarterly installments commencing on March 31, 2027, subject to the Reporting Person continuing to serve as a director of the Issuer on each applicable vesting date. F1 · derivative.exercise_date: The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Compensation Committee of the Board of Directors. The non-qualified stock options are granted under the Issuer's 2025 Equity Incentive Plan and the exercisability shall be subject to execution of the Issuer's form of Non-Qualified Stock Option Agreement. The non-qualified stock options shall vest as follows: one-half shall vest and become exercisable on January 9, 2027 and the remaining half shall vest and become exercisable in eight equal quarterly installments commencing on March 31, 2027, subject to the Reporting Person continuing to serve as a director of the Issuer on each applicable vesting date. Read SEC document
January 02, 2026 Filed Jan 6, 2026 21:06 UTC	EyePoint, Inc. EYPT · Entity 5702	GrantStock Option (Right to Buy) · Derivative	40,000	$0.00 Strike: $17.48	$0.00	Disclosure SEC source: 0001110744-26-000002 · primarydocument.xml · derivative · entry 1 Hassan Fred · CIK 0001110744 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2036-01-02 Read SEC document
October 28, 2025 Filed Oct 30, 2025 20:15 UTC	Cocrystal Pharma, Inc. COCP · Entity 7621	GrantWarrants · Derivative	719,426	$1.39 Strike: $1.24	$1,000,002.14	Disclosure SEC source: 0001493152-25-020221 · ownership.xml · derivative · entry 2 Hassan Fred · CIK 0001110744 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 719,426 Underlying: Common Stock · 719,426 shares Expires 2028-01-28 F1 · security: The Reporting Person purchased units at $1.39 per unit with each unit consisting of one share of common stock and a warrant to purchase two shares of common stock. The shares of common stock and warrants purchased are exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by a Special Committee of the Board of Directors of the Issuer, which Special Committee consisted of two non-employee directors. The warrants were exercisable upon issuance. F1 · derivative.exercise_date: The Reporting Person purchased units at $1.39 per unit with each unit consisting of one share of common stock and a warrant to purchase two shares of common stock. The shares of common stock and warrants purchased are exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by a Special Committee of the Board of Directors of the Issuer, which Special Committee consisted of two non-employee directors. The warrants were exercisable upon issuance. Read SEC document
October 28, 2025 Filed Oct 30, 2025 20:15 UTC	Cocrystal Pharma, Inc. COCP · Entity 7621	GrantCommon Stock	359,713	$1.39	$500,001.07	Disclosure SEC source: 0001493152-25-020221 · ownership.xml · nonDerivative · entry 1 Hassan Fred · CIK 0001110744 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,383,009 F1 · security: The Reporting Person purchased units at $1.39 per unit with each unit consisting of one share of common stock and a warrant to purchase two shares of common stock. The shares of common stock and warrants purchased are exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by a Special Committee of the Board of Directors of the Issuer, which Special Committee consisted of two non-employee directors. The warrants were exercisable upon issuance. F2 · balance_after: Includes shares of common stock issuable upon vesting of restricted stock units. Read SEC document
June 20, 2025 Filed Jun 24, 2025 22:56 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	GrantStock Option (Right to Buy) · Derivative	8,425	$0.00 Strike: $41.73	$0.00	Disclosure SEC source: 0000950170-25-089647 · ownership.xml · derivative · entry 2 Hassan Fred · CIK 0001110744 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,425 Underlying: Common Stock · 8,425 shares Expires 2035-06-19 F3 · derivative.exercise_date: One-third of the shares underlying the stock option will vest each year after June 20, 2025, such that all of the underlying shares will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors. Read SEC document
June 20, 2025 Filed Jun 24, 2025 22:56 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	GrantCommon Stock	6,589	$0.00	$0.00	Disclosure SEC source: 0000950170-25-089647 · ownership.xml · nonDerivative · entry 1 Hassan Fred · CIK 0001110744 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,889 F1 · kind: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. One-third of the RSUs will vest each year after June 20, 2025, such that all of the units will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document
March 14, 2025 Filed Mar 17, 2025 22:33 UTC	PRECIGEN, INC. PGEN · Entity 4356	Exercise / conversionRestricted Stock Units · Derivative	87,412	$0.00	$0.00	Disclosure SEC source: 0000950103-25-003518 · dp226401_4-hassan.xml · derivative · entry 4 Hassan Fred · CIK 0001110744 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 87,412 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. F4 · derivative.exercise_date: The RSUs vested in full on March 14, 2025. F4 · derivative.expiration_date: The RSUs vested in full on March 14, 2025. Read SEC document
March 14, 2025 Filed Mar 17, 2025 22:33 UTC	PRECIGEN, INC. PGEN · Entity 4356	Exercise / conversionCommon Stock	87,412	Not disclosed	Not disclosed	Disclosure SEC source: 0000950103-25-003518 · dp226401_4-hassan.xml · nonDerivative · entry 2 Hassan Fred · CIK 0001110744 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,153,452 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. Read SEC document
March 13, 2025 Filed Mar 17, 2025 22:33 UTC	PRECIGEN, INC. PGEN · Entity 4356	GrantOption to Purchase Common Stock (Right to Buy) · Derivative	83,517	$0.00 Strike: $1.74	$0.00	Disclosure SEC source: 0000950103-25-003518 · dp226401_4-hassan.xml · derivative · entry 5 Hassan Fred · CIK 0001110744 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,517 Underlying: Common Stock · 83,517 shares Expires 2035-03-13 Read SEC document
March 13, 2025 Filed Mar 17, 2025 22:33 UTC	PRECIGEN, INC. PGEN · Entity 4356	GrantRestricted Stock Units · Derivative	71,839	$0.00	$0.00	Disclosure SEC source: 0000950103-25-003518 · dp226401_4-hassan.xml · derivative · entry 3 Hassan Fred · CIK 0001110744 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,839 Underlying: Common Stock · 71,839 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. F3 · derivative.exercise_date: The RSUs vest in full on March 13, 2026. F3 · derivative.expiration_date: The RSUs vest in full on March 13, 2026. Read SEC document
March 13, 2025 Filed Mar 17, 2025 22:33 UTC	PRECIGEN, INC. PGEN · Entity 4356	GrantCommon Stock	36,206	$1.74	$62,998.44	Disclosure SEC source: 0000950103-25-003518 · dp226401_4-hassan.xml · nonDerivative · entry 1 Hassan Fred · CIK 0001110744 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,066,040 F1 · price: The shares were issued to the reporting person in lieu of an annual retainer of $63,000. Read SEC document
January 03, 2025 Filed Jan 7, 2025 21:05 UTC	EyePoint, Inc. EYPT · Entity 5702	GrantStock Option (Right to Buy) · Derivative	40,000	$0.00 Strike: $8.26	$0.00	Disclosure SEC source: 0001562180-25-000235 · primarydocument.xml · derivative · entry 1 Hassan Fred · CIK 0001110744 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2035-01-03 Read SEC document
October 09, 2024 Filed Oct 11, 2024 20:05 UTC	Cocrystal Pharma, Inc. COCP · Entity 7621	GrantCommon Stock	8,067	Not disclosed	Not disclosed	Disclosure SEC source: 0001493152-24-040899 · ownership.xml · nonDerivative · entry 1 Hassan Fred · CIK 0001110744 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,023,296 F1 · security: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The grant is exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by the Board of Directors of the Issuer. One half of the RSUs are fully vested, with the balance vesting in eight equal quarterly installments on the last day of each quarter commencing with the quarter ending September 30, 2025, subject to continued services for the Company as of each applicable vesting date. Shares of common stock will be delivered to the Reporting Person promptly upon vesting, unless the Reporting Person elects to defer delivery. The RSUs were granted under the Issuer's 2015 Equity Incentive Plan and will vest in full upon a Change of Control as defined in such Plan. F1 · price: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The grant is exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by the Board of Directors of the Issuer. One half of the RSUs are fully vested, with the balance vesting in eight equal quarterly installments on the last day of each quarter commencing with the quarter ending September 30, 2025, subject to continued services for the Company as of each applicable vesting date. Shares of common stock will be delivered to the Reporting Person promptly upon vesting, unless the Reporting Person elects to defer delivery. The RSUs were granted under the Issuer's 2015 Equity Incentive Plan and will vest in full upon a Change of Control as defined in such Plan. Read SEC document
September 03, 2024 Filed Sep 5, 2024 20:02 UTC	EyePoint, Inc. EYPT · Entity 5702	GrantStock Options (Right to buy) · Derivative	60,000	$0.00 Strike: $8.16	$0.00	Disclosure SEC source: 0001562180-24-006671 · primarydocument.xml · derivative · entry 1 Hassan Fred · CIK 0001110744 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2034-09-03 F1 · derivative.exercise_date: The option becomes exercisable in three ratable annual installments beginning on September 3, 2025. Read SEC document
June 21, 2024 Filed Jun 25, 2024 21:39 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	GrantStock Option (Right to Buy) · Derivative	26,014	$0.00 Strike: $27.36	$0.00	Disclosure SEC source: 0000950170-24-077444 · ownership.xml · derivative · entry 1 Hassan Fred · CIK 0001110744 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,014 Underlying: Common Stock · 26,014 shares Expires 2034-06-20 F1 · derivative.exercise_date: One-third of the shares underlying the stock option will vest each year after June 21, 2024, such that all of the underlying shares will be vested on June 21, 2027, subject to the Reporting Person's continued service on the board of directors of the Issuer. Read SEC document
March 14, 2024 Filed Mar 18, 2024 22:20 UTC	PRECIGEN, INC. PGEN · Entity 4356	GrantOption to Purchase Common Stock (Right to Buy) · Derivative	101,626	$0.00 Strike: $1.43	$0.00	Disclosure SEC source: 0000950103-24-003955 · dp208508_4-hassan.xml · derivative · entry 3 Hassan Fred · CIK 0001110744 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,626 Underlying: Common Stock · 101,626 shares Expires 2034-03-14 Read SEC document
March 14, 2024 Filed Mar 18, 2024 22:20 UTC	PRECIGEN, INC. PGEN · Entity 4356	GrantRestricted Stock Units · Derivative	87,412	$0.00	$0.00	Disclosure SEC source: 0000950103-24-003955 · dp208508_4-hassan.xml · derivative · entry 2 Hassan Fred · CIK 0001110744 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,412 Underlying: Common Stock · 87,412 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. F3 · derivative.exercise_date: The RSUs vest in full on March 14, 2025. F3 · derivative.expiration_date: The RSUs vest in full on March 14, 2025. Read SEC document
March 14, 2024 Filed Mar 18, 2024 22:20 UTC	PRECIGEN, INC. PGEN · Entity 4356	GrantCommon Stock	44,055	$1.43	$62,998.65	Disclosure SEC source: 0000950103-24-003955 · dp208508_4-hassan.xml · nonDerivative · entry 1 Hassan Fred · CIK 0001110744 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,029,834 F1 · price: The shares were issued to the reporting person in lieu of an annual retainer of $62,999. Read SEC document
March 09, 2024 Filed Mar 12, 2024 23:53 UTC	PRECIGEN, INC. PGEN · Entity 4356	Exercise / conversionRestricted Stock Units · Derivative	106,837	$0.00	$0.00	Disclosure SEC source: 0000950103-24-003746 · dp208299_4-hassan.xml · derivative · entry 2 Hassan Fred · CIK 0001110744 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 106,837 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. F2 · derivative.exercise_date: The RSUs vested in full on March 9, 2024. F2 · derivative.expiration_date: The RSUs vested in full on March 9, 2024. Read SEC document
March 09, 2024 Filed Mar 12, 2024 23:53 UTC	PRECIGEN, INC. PGEN · Entity 4356	Exercise / conversionCommon Stock	106,837	Not disclosed	Not disclosed	Disclosure SEC source: 0000950103-24-003746 · dp208299_4-hassan.xml · nonDerivative · entry 1 Hassan Fred · CIK 0001110744 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 985,779 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. Read SEC document
August 14, 2023 Filed Aug 16, 2023 20:31 UTC	PRECIGEN, INC. PGEN · Entity 4356	PurchaseCommon Stock	570,345	$1.75	$998,103.75	Disclosure SEC source: 0000950103-23-012143 · dp198564_4-hassan.xml · nonDerivative · entry 1 Hassan Fred · CIK 0001110744 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 878,942 F1 · shares: These shares were purchased under an account held jointly by the reporting person and the reporting person's spouse. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.69 to $1.76, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document
July 18, 2023 Filed Jul 20, 2023 20:05 UTC	Cocrystal Pharma, Inc. COCP · Entity 7621	GrantStock Options (Right to Buy) · Derivative	7,333	$0.00 Strike: $2.67	$0.00	Disclosure SEC source: 0001493152-23-025080 · ownership.xml · derivative · entry 1 Hassan Fred · CIK 0001110744 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,333 Underlying: Common Stock · 7,333 shares Expires 2033-07-18 F1 · derivative.exercise_date: The stock options were issued pursuant to the 2015 Equity Incentive Plan and vest as follows: one-half will vest and become exercisable on July 18, 2024 and the remaining half will vest and become exercisable in eight equal quarterly installments on the last day of March, June, September, and December commencing on September 30, 2024, subject to the reporting person continuing to serve as a director of the Company on each applicable vesting date. Read SEC document
June 21, 2023 Filed Jun 23, 2023 20:19 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	GrantStock Option (right to buy) · Derivative	51,501	$0.00 Strike: $16.75	$0.00	Disclosure SEC source: 0001209191-23-039375 · doc4.xml · derivative · entry 1 Hassan Fred · CIK 0001110744 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,501 Underlying: Common Stock · 51,501 shares Expires 2033-06-21 F1 · derivative.exercise_date: 1/3rd of the shares underlying the option will vest on June 21, 2024; thereafter, 1/3rd of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 21, 2026, subject to the optionee's continued service on the Board of Directors of the Company. Read SEC document
June 16, 2023 Filed Jun 16, 2023 20:00 UTC	Prometheus Biosciences, Inc. RXDX · Entity 112175	Disposition to issuerStock Option (right to buy) · Derivative	21,013	Not disclosed Strike: $29.02	Not disclosed	Disclosure SEC source: 0000899243-23-015758 · doc4.xml · derivative · entry 4 Hassan Fred · CIK 0001110744 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,013 shares Expires 2032-05-18 F2 · price: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,.. (Continued in Footnote 3) F3 · price: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option. F2 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,.. (Continued in Footnote 3) F3 · derivative.exercise_date: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option. Read SEC document
June 16, 2023 Filed Jun 16, 2023 20:00 UTC	Prometheus Biosciences, Inc. RXDX · Entity 112175	Disposition to issuerStock Option (right to buy) · Derivative	541	Not disclosed Strike: $36.32	Not disclosed	Disclosure SEC source: 0000899243-23-015758 · doc4.xml · derivative · entry 3 Hassan Fred · CIK 0001110744 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 541 shares Expires 2031-11-13 F2 · price: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,.. (Continued in Footnote 3) F3 · price: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option. F2 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,.. (Continued in Footnote 3) F3 · derivative.exercise_date: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option. Read SEC document
June 16, 2023 Filed Jun 16, 2023 20:00 UTC	Prometheus Biosciences, Inc. RXDX · Entity 112175	Disposition to issuerStock Option (right to buy) · Derivative	40,000	Not disclosed Strike: $16.82	Not disclosed	Disclosure SEC source: 0000899243-23-015758 · doc4.xml · derivative · entry 2 Hassan Fred · CIK 0001110744 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2031-05-13 F2 · price: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,.. (Continued in Footnote 3) F3 · price: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option. F2 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,.. (Continued in Footnote 3) F3 · derivative.exercise_date: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option. Read SEC document
June 16, 2023 Filed Jun 16, 2023 20:00 UTC	Prometheus Biosciences, Inc. RXDX · Entity 112175	Disposition to issuerCommon Stock	2,123	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-23-015758 · doc4.xml · nonDerivative · entry 1 Hassan Fred · CIK 0001110744 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Reflects restricted stock units. F2 · price: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,.. (Continued in Footnote 3) F3 · price: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option. Read SEC document
May 19, 2023 Filed May 19, 2023 21:39 UTC	Prometheus Biosciences, Inc. RXDX · Entity 112175	GrantCommon Stock	2,123	$0.00	$0.00	Disclosure SEC source: 0001209191-23-031175 · doc4.xml · nonDerivative · entry 1 Hassan Fred · CIK 0001110744 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,123 F1 · kind: Award of restricted stock units ("RSUs") granted under the Issuer's 2021 Incentive Award Plan (the "2021 Plan"). Each RSU entitles the Reporting Person to receive one share of Issuer common stock upon vesting. The RSUs shall vest in full upon the earlier to occur of (i) the first anniversary of the date of grant, (ii) the Issuer's next occurring annual meeting of stockholders, or (iii) a Change of Control (as defined in the 2021 Plan), subject to the Reporting Person's continued service with the Issuer on such vesting date. Read SEC document
March 09, 2023 Filed Mar 13, 2023 21:02 UTC	PRECIGEN, INC. PGEN · Entity 4356	GrantOption to Purchase Common Stock (Right to Buy) · Derivative	125,489	$0.00 Strike: $1.17	$0.00	Disclosure SEC source: 0000950103-23-004007 · dp190523_4-hassan.xml · derivative · entry 3 Hassan Fred · CIK 0001110744 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,489 Underlying: Common Stock · 125,489 shares Expires 2033-03-09 Read SEC document
March 09, 2023 Filed Mar 13, 2023 21:02 UTC	PRECIGEN, INC. PGEN · Entity 4356	GrantRestricted Stock Units · Derivative	106,837	$0.00	$0.00	Disclosure SEC source: 0000950103-23-004007 · dp190523_4-hassan.xml · derivative · entry 2 Hassan Fred · CIK 0001110744 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,837 Underlying: Common Stock · 106,837 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ('RSU") represents a contingent right to receive one share of Precigen common stock. F3 · derivative.exercise_date: The RSUs vest in full on March 9, 2024. F3 · derivative.expiration_date: The RSUs vest in full on March 9, 2024. Read SEC document
March 09, 2023 Filed Mar 13, 2023 21:02 UTC	PRECIGEN, INC. PGEN · Entity 4356	GrantCommon Stock	48,290	$1.17	$56,499.30	Disclosure SEC source: 0000950103-23-004007 · dp190523_4-hassan.xml · nonDerivative · entry 1 Hassan Fred · CIK 0001110744 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,597 F1 · price: The shares were issued to the reporting person in lieu of an annual retainer of $56,500. Read SEC document
February 22, 2023 Filed Feb 25, 2023 01:09 UTC	PRECIGEN, INC. PGEN · Entity 4356	Exercise / conversionRestricted Stock Units · Derivative	61,576	$0.00	$0.00	Disclosure SEC source: 0000950103-23-003029 · dp189562_4-hassan.xml · derivative · entry 2 Hassan Fred · CIK 0001110744 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 61,576 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. F2 · derivative.exercise_date: The RSUs vested in full on February 22, 2023. F2 · derivative.expiration_date: The RSUs vested in full on February 22, 2023. Read SEC document
February 22, 2023 Filed Feb 25, 2023 01:09 UTC	PRECIGEN, INC. PGEN · Entity 4356	Exercise / conversionCommon Stock	61,576	Not disclosed	Not disclosed	Disclosure SEC source: 0000950103-23-003029 · dp189562_4-hassan.xml · nonDerivative · entry 1 Hassan Fred · CIK 0001110744 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,307 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. Read SEC document
June 22, 2022 Filed Jun 24, 2022 20:29 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	GrantStock Option (right to buy) · Derivative	104,921	$0.00 Strike: $8.45	$0.00	Disclosure SEC source: 0001209191-22-039243 · doc4.xml · derivative · entry 1 Hassan Fred · CIK 0001110744 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,921 Underlying: Common Stock · 104,921 shares Expires 2032-06-22 F1 · derivative.exercise_date: 1/3rd of the shares underlying the option will vest on June 22, 2023; thereafter, 1/3rd of the remaining underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on the June 22, 2025, subject to the optionee's continued service on the Board of Directors of the Company. Read SEC document
May 19, 2022 Filed May 20, 2022 23:20 UTC	Prometheus Biosciences, Inc. RXDX · Entity 112175	GrantStock Option (Right to Buy) · Derivative	21,013	$0.00 Strike: $29.02	$0.00	Disclosure SEC source: 0001209191-22-031173 · doc4.xml · derivative · entry 1 Hassan Fred · CIK 0001110744 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,013 Underlying: Common Stock · 21,013 shares Expires 2032-05-18 F1 · derivative.exercise_date: The shares subject to the option will vest in full upon the earlier to occur of (i) the first anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service with the Issuer on such vesting date. Read SEC document
March 25, 2022 Filed Mar 29, 2022 21:04 UTC	PRECIGEN, INC. PGEN · Entity 4356	Exercise / conversionRestricted Stock Units · Derivative	16,212	$0.00	$0.00	Disclosure SEC source: 0000950103-22-005404 · dp170033_4-hassan.xml · derivative · entry 2 Hassan Fred · CIK 0001110744 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,212 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. F2 · derivative.exercise_date: The RSUs vested in full on March 25, 2022. F2 · derivative.expiration_date: The RSUs vested in full on March 25, 2022. Read SEC document
March 25, 2022 Filed Mar 29, 2022 21:04 UTC	PRECIGEN, INC. PGEN · Entity 4356	Exercise / conversionCommon Stock	16,212	Not disclosed	Not disclosed	Disclosure SEC source: 0000950103-22-005404 · dp170033_4-hassan.xml · nonDerivative · entry 1 Hassan Fred · CIK 0001110744 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,731 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. Read SEC document
February 22, 2022 Filed Feb 24, 2022 22:48 UTC	PRECIGEN, INC. PGEN · Entity 4356	GrantOption to Purchase Common Stock (Right to Buy) · Derivative	83,189	$0.00 Strike: $2.03	$0.00	Disclosure SEC source: 0000950103-22-003221 · dp167775_4-hassan.xml · derivative · entry 3 Hassan Fred · CIK 0001110744 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,189 Underlying: Common Stock · 83,189 shares Expires 2032-02-22 Read SEC document
February 22, 2022 Filed Feb 24, 2022 22:48 UTC	PRECIGEN, INC. PGEN · Entity 4356	GrantRestricted Stock Units · Derivative	61,576	$0.00	$0.00	Disclosure SEC source: 0000950103-22-003221 · dp167775_4-hassan.xml · derivative · entry 2 Hassan Fred · CIK 0001110744 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,576 Underlying: Common Stock · 61,576 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ('RSU") represents a contingent right to receive one share of Precigen common stock. F3 · derivative.exercise_date: The RSUs vest in full on February 22, 2023. F3 · derivative.expiration_date: The RSUs vest in full on February 22, 2023. Read SEC document
February 22, 2022 Filed Feb 24, 2022 22:48 UTC	PRECIGEN, INC. PGEN · Entity 4356	GrantCommon Stock	27,832	$2.03	$56,498.96	Disclosure SEC source: 0000950103-22-003221 · dp167775_4-hassan.xml · nonDerivative · entry 1 Hassan Fred · CIK 0001110744 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,519 F1 · price: The shares were issued to the reporting person in lieu of an annual retainer of $56,500. Read SEC document
December 29, 2021 Filed Jan 4, 2022 00:50 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	PurchaseCommon Stock	19,300	$14.17	$273,390.29	Disclosure SEC source: 0000899243-22-000176 · doc4.xml · nonDerivative · entry 1 Hassan Fred · CIK 0001110744 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,300 F1 · price: Represents the weighted average purchase price of the shares purchased from $14.1250 to $14.2300 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions as reported in this footnote. Read SEC document
November 14, 2021 Filed Nov 17, 2021 02:19 UTC	Prometheus Biosciences, Inc. RXDX · Entity 112175	GrantStock Option (Right to Buy) · Derivative	541	$0.00 Strike: $36.32	$0.00	Disclosure SEC source: 0001209191-21-064942 · doc4.xml · derivative · entry 1 Hassan Fred · CIK 0001110744 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 541 Underlying: Common Stock · 541 shares Expires 2031-11-13 F1 · derivative.exercise_date: The shares subject to the option will vest on the first anniversary of the vesting commencement date measured from November 14, 2021, subject to the Reporting Person's continued service with the Issuer on such vesting date. Read SEC document
August 17, 2021 Filed Aug 26, 2021 21:14 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	GrantStock Option (right to buy) · Derivative	49,869	$0.00 Strike: $49.54	$0.00	Disclosure SEC source: 0000899243-21-034291 · doc4.xml · derivative · entry 1 Hassan Fred · CIK 0001110744 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,869 Underlying: Common Stock · 49,869 shares Expires 2031-08-16 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in three annual installments after August 17, 2021, subject to the Reporting Person's continued service on the Issuer's Board of Directors through each such date. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.